Previous 10 | Next 10 |
Adaptimmune Therapeutics plc (ADAP) Q1 2020 Earnings Conference Call May 14, 2020, 08:00 AM ET Company Participants Juli Miller - Director of IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participa...
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP) Q1 2020 Earnings Call May 14, 2020 , 8:00 a.m. ET Operator Continue reading
Adaptimmune (NASDAQ: ADAP ): Q1 GAAP EPS of -$0.04 beats by $0.21 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU a...
CymaBay Therapeutics (NASDAQ: CBAY ) +147% on upgrades and Q1 results . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., NanoViricides, Inc., News on the U.S. economy Read more ...
- Edited stem-cell derived T-cells can kill MAGE-A4 + cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for clinical use - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Ther...
- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before ...
The EMA's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation (ODD) for Adaptimmune Therapeutics' (NASDAQ: ADAP ) ADP-A2M4 for the treatment of soft tissue sarcomas. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a posi...
Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate shares of ADAP with a Neutral and a $3 price target. We see the efforts to develop a TCR-based treatment for solid tumors a...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...